PF-Atlas › Clinical Trials › NCT05844449

Evaluation of Long-Term Safety and Efficacy of Vanzacaftor/Tezacaftor/Deutivacaftor in Cystic Fibrosis Participants 1 Year of Age and Older

VNZ/TEZ/D-IVA · Phase 3

Registry ID

NCT05844449

Phase

Phase 3

Status

Enrolling by invitation

Drug / intervention

VNZ/TEZ/D-IVA

Sponsor

Vertex Pharmaceuticals Incorporated

Start

2023-08-11

About this trial

VNZ/TEZ/D-IVA is evaluated in NCT05844449, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Vertex Pharmaceuticals Incorporated. Current status: Enrolling by invitation.

View NCT05844449 on ClinicalTrials.gov →

Explore related

All VNZ/TEZ/D-IVA trials All IPF trials

Related trials

VNZ/TEZ/D-IVA — NCT07349394

Medical disclaimer. This page summarizes public trial data for NCT05844449 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.